Kiji Therapeutics is developing a therapeutic to treat autoimmune diseases, using genetically engineered mesenchymal stem cells to improve potency and targeting. The drug is targeted towards patients with graft versus host disease, an autoimmune disease that occurs in bone marrow recipients. CEO Miguel Forte says the firm is exploring partnering with larger companies to commercialize its products. Earlier plans for a merger with Taiwanese company REGiMMUNE have been abandoned although other partnerships may be explored in future.
Experts Uncover New XorDDoS Controller, Infrastructure as Malware Expands to Docker, Linux, IoT
Cybersecurity researchers have highlighted the ongoing risk posed by XorDDoS, a distributed denial-of-service malware that has targeted the US in 71.3% of attacks from November
